Clinical Trials Directory

Trials / Terminated

TerminatedNCT04879706

Proenkephalin A and Kidney Replacement Therapy

Proenkephalin A at Initiation and Discontinuation of Kidney Replacement Therapy

Status
Terminated
Phase
Study type
Observational
Enrollment
6 (actual)
Sponsor
University of Giessen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Acute kidney injury (AKI) is a common problem encountered in the intensive care unit (ICU), estimated to occur in up to 60% of all critically ill patients, depending on the definition. Recent large randomized clinical trials in critical care nephrology have focused on the optimal timing of initiation of acute kidney replacement therapy (KRT). However, less is known about the ideal circumstances in which KRT may be successfully discontinued. The novel serum-biomarker proenkephalin A 119-159 (penkid) has been found to be strongly negatively correlated with measured GFR. Whether penkid may have a role in initiation and discontinuation of KRT remains unknown.

Detailed description

Acute kidney injury (AKI) is a common problem encountered in the intensive care unit (ICU), estimated to occur in up to 60% of all critically ill patients, depending on the definition. Recent large randomized clinical trials in critical care nephrology have focused on the optimal timing of initiation of acute kidney replacement therapy (KRT). However, less is known about the ideal circumstances in which KRT may be successfully discontinued. KRT is a complex and expensive therapy, with complications including catheter-associated infections, hemorrhage, hemodynamic instability, and potential delayed renal recovery. The novel serum-biomarker proenkephalin A 119-159 (penkid) is a stable fragment derived from the precursor enkephalins, which are known as small endogenous opioid peptides and are produced throughout the human body, including the kidneys. Plasma concentrations of penkid have been found to be strongly negatively correlated with measured glomerular filtration rate. Whether penkid may have a role in initiation and discontinuation of KRT remains unknown.

Conditions

Interventions

TypeNameDescription
OTHERNone plannedNo intervention planned

Timeline

Start date
2021-11-09
Primary completion
2023-01-21
Completion
2023-01-21
First posted
2021-05-10
Last updated
2023-12-01

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT04879706. Inclusion in this directory is not an endorsement.